Cerevel Therapeutics, LLC

Amylyx Pharmaceuticals, Inc., based in Cambridge, MA, is dedicated to developing innovative therapies for communities with significant unmet medical needs. With a strong commitment to advancing rigorous scientific research, the company focuses on delivering solutions for challenging diseases such as post-bariatric hypoglycemia, Wolfram syndrome, progressive supranuclear palsy, and amyotrophic lateral sclerosis. Rooted in the belief that connections drive progress, Amylyx intertwines the perspectives of affected individuals, their families, and renown medical insights to inform its mission. The company prides itself on fostering a culture of compassion and collaboration within its team, dedicated to addressing the unique challenges faced by patients and their support systems. Generated from the website

Omega Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, focused on advancing therapeutic solutions through its innovative approach to genetic medicine. The company is dedicated to leveraging its unique platform to address significant unmet medical needs. Currently, Omega Therapeutics is working on developing its domain and online presence as part of its operational infrastructure. This enhancement aims to bolster its engagement and communication within the biotechnology sector. Generated from the website

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.